- Home
- SEED vs TXMD Comparison
SEED vs TXMD Comparison
Compare SEED & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- TXMD
- Stock Information
- Founded
- SEED 1997
- TXMD 2008
- Country
- SEED China
- TXMD United States
- Employees
- SEED N/A
- TXMD N/A
- Industry
- SEED Farming/Seeds/Milling
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- SEED Consumer Staples
- TXMD Health Care
- Exchange
- SEED Nasdaq
- TXMD Nasdaq
- Market Cap
- SEED 18.3M
- TXMD 17.9M
- IPO Year
- SEED N/A
- TXMD N/A
- Fundamental
- Price
- SEED $2.30
- TXMD $1.41
- Analyst Decision
- SEED
- TXMD
- Analyst Count
- SEED 0
- TXMD 0
- Target Price
- SEED N/A
- TXMD N/A
- AVG Volume (30 Days)
- SEED 22.4K
- TXMD 17.4K
- Earning Date
- SEED 11-29-2024
- TXMD 11-12-2024
- Dividend Yield
- SEED N/A
- TXMD N/A
- EPS Growth
- SEED N/A
- TXMD N/A
- EPS
- SEED 1.21
- TXMD N/A
- Revenue
- SEED $16,516,031.00
- TXMD $1,596,000.00
- Revenue This Year
- SEED N/A
- TXMD $605.07
- Revenue Next Year
- SEED N/A
- TXMD $1.11
- P/E Ratio
- SEED $1.90
- TXMD N/A
- Revenue Growth
- SEED 64.93
- TXMD N/A
- 52 Week Low
- SEED $1.37
- TXMD $1.38
- 52 Week High
- SEED $6.38
- TXMD $3.07
- Technical
- Relative Strength Index (RSI)
- SEED 34.00
- TXMD 19.09
- Support Level
- SEED $2.49
- TXMD $1.47
- Resistance Level
- SEED $2.78
- TXMD $1.58
- Average True Range (ATR)
- SEED 0.22
- TXMD 0.06
- MACD
- SEED -0.03
- TXMD -0.01
- Stochastic Oscillator
- SEED 25.00
- TXMD 13.23
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.